Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $28.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 138.10% from the stock’s previous close. OCS has been the subject […]
Oculis (NASDAQ:OCS – Get Free Report) is one of 986 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Oculis to related companies based on the strength of its profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Institutional & Insider Ownership 22.3% of Oculis […]
Oculis (NASDAQ:OCS – Get Free Report) is one of 968 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Oculis to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, valuation, profitability and earnings. Institutional & Insider Ownership 22.3% […]
OCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024 biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company") a global biopharmaceutical company purposefully driven to save sight and